Trial Profile
A Randomized, Double-masked Study With Intraocular Anti-VEGF (Avastin/Lucentis) Compared With Intraocular Triamcinolone (Volon A) in Patients With Clinical Significant Diabetic Macular Edema
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Ranibizumab (Primary) ; Triamcinolone
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Acronyms TRIASTIN
- 01 Jan 2018 Results (n=25) of post hoc analysis of morphologic characteristics in OCT, FA and CF images assessing the effect of ranibizumab vs triamcinolone on changes in retinal morphology published in the Graefes Archive for Clinical and Experimental Ophthalmology
- 03 Mar 2016 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
- 31 May 2013 Planned end date changed from 1 Oct 2009 to 1 Dec 2014 as reported by ClinicalTrials.gov.